MacroGenics, Inc. (NASDAQ:MGNX – Free Report) – Investment analysts at B. Riley issued their FY2024 EPS estimates for shares ...
Philadelphia, Pennsylvania--(Newsfile Corp. - November 13, 2024) - Grabar Law Office is actively investigating claims on behalf of MacroGenics, Inc. (NASDAQ: MGNX) shareholders. If you have ...
Hosted on MSN6d
JMP Securities Downgrades MacroGenics (MGNX)Fintel reports that on November 7, 2024, JMP Securities downgraded their outlook for MacroGenics (NasdaqGS:MGNX) from Market ...
MacroGenics (the Company) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The ...
Ideaya Biosciences has decided to go ahead with its plans to grab a bispecific antibody-drug conjugate (ADC) from Biocytogen, exercising an option to pick up a preclinical asset from the Chinese ...
with clinical-stage candidates from GSK and MacroGenics. SCLC is the second most common type of lung cancer, accounting for about 15% of all lung cancers, with overexpression of B7-H3 seen in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback